
DataMeds AI issues 630,000 shares in cancer partnership
Key points
- DataMeds AI announced a cancer drug discovery partnership between its subsidiary Helomics and DiaGen AI, covering an initial programme involving 15 peptides.
- DataMeds will issue 630,000 common shares, representing 9.9% of its outstanding shares, in exchange for a 9.9% interest in DiaGen AI.
- The partnership involves $1.5 million in cash and in-kind contributions, with initial research focused on identifying potential drug targets in breast cancer, including triple-negative breast cancer.
DataMeds AI (NASDAQ:MEDS) announced that its subsidiary Helomics entered a cancer drug discovery partnership with DiaGen AI, involving 15 experimental peptides and an expected $1.5 million in research contributions.
The initial programme will evaluate 15 cytotoxic peptides identified through DiaGen's CYPRESS platform, which have demonstrated proof of concept in breast cancer cell lines, including triple-negative breast cancer, although their mechanism of action remains undetermined.
"Being able to access this robust primary tumor biobank and Helomics' proprietary capabilities to identify new therapeutic targets and leverage our proprietary BLACKCOMB artificial intelligence chemical drug discovery platform to design the best candidates for human clinical development is a transformative opportunity for DiaGen," said Dr. Mohit Pandey, chief AI officer of DiaGen AI.
Under the agreement, DataMeds will issue 630,000 common shares to DiaGen, representing 9.9% of its outstanding shares, in exchange for a 9.9% interest in DiaGen's fully diluted shares, while DataMeds will cover up to 50% of computing expenses and DiaGen will fund laboratory testing costs.
Helomics maintains a biobank containing more than 70,000 primary tumour biopsies, including over 50,000 gynaecological cancer samples, alongside proprietary cell-painting technology and three-dimensional tumour testing capabilities.
The partners plan to investigate additional cancer types, including ovarian, pancreatic, lung and brain cancers, if the initial research identifies therapeutic targets with broader applications, with intellectual property generated through the discovery programme to be jointly owned.

